By clicking on the button, you agree to the privacy policy
Contact us
Leave your contact details and we will contact you!

Rapid DIAGNOSTIC tests for COVID-19

Rapid tests for SARS-COV-2 antigen and antibodies. Proprietary developed and manufactured in Technopark (Moscow). Registration certificates for a medical device:
1) Rapid test for COVID-19 antibodies No. RZN 2020/10917 dated June 17, 2020;
2) Rapid test for COVID-19 antibodies to RBD domain S No. RZN 2021/13741 dated March 16, 2021 issued by the Federal Service "Roszdravnadzor"
3) Rapid test for COVID-19 antigen No. RZN 2020/12901 dated 12/11/2020 issued by the Federal Service "Roszdravnadzor"




About

We are engaged in the development of rapid diagnostic tests for Healthcare and food safety.

Our goal - is the creation of affordable and accurate rapid diagnostics for health care, veterinary diagnostics, and food safety.
Rapid Bio's laboratory and production facilities are located in the Moscow Technopark and are certified according to the ISO 13485 standard.
Our team - outstanding professionals in the field of biotechnology, development and production of rapid tests.
We create the future today for the benefit of mankind!
Products

Our company develops fast and accurate rapid tests for diagnostics near the patient.

Thanks to a wonderful team of biotechnologists and research scientists, we create in our laboratory medical devices of the highest level according to the best international standards.
More about products:
High sensitivity and specificity, convenient and fast alternative to PCR.
Registration certificate for a medical device
No. RZN 2020/12901 dated 11.12.2020 issued by the Federal Service "Roszdravnadzor"
CE-mark, Thailand FDA approved
High sensitivity and specificity, convenient and fast alternative to PCR
Rapid tests for COVID-19 antigen
Proprietary development and modern production in the Moscow Technopark
Registration certificate for a medical device
No. RZN 2020/10917 dated June 17, 2020 issued by the Federal Service "Roszdravnadzor"
Funded by hundreds of crowdfunders
One of the first tests developed worldwide
Rapid tests for COVID-19 IgG / IgM antibodies
Proprietary development and modern production in the MoscowTechnopark
Registration certificate for a medical device
No. RZN 2021/13741 dated March 16, 2021 issued by the Federal Service "Roszdravnadzor"
Exclusive distributor of AVIVIR LLC
Post vaccination immunity status
Rapid tests for COVID-19 IgG antibodies to RBD domain S glycoprotein
* - the test was developed with the support of 570 project sponsors as part of the crowdfunding program at www.boomstarter.ru
The test is intended for the qualitative determination of IgG and IgM antibodies to SARS-COV-2 in serum, plasma, or whole blood.

Together with you* we have developed a rapid test for antibodies to COVID-19.

In development

Rapid Bio develops new tests:

Rapid test for the determination of the antigen of group A Streptococcus pyogenes (Streptococcus A) by a throat swab

Streptococcus A

Rapid test for the detection of influenza virus serotypes A and B (Influenza virus A / B) in the patient's nasopharyngeal smear

Influenza A / B

Rapid test to determine the level of procalcitonin in the blood for the diagnosis of sepsis, septic complications, severe bacterial infections and purulent-inflammatory processes.

Procalcitonin

Rapid test for the determination of D-dimer (a marker of thrombus formation).
D-dimer is a protein fragment that is formed when a blood clot that occurs during blood clotting dissolves.

D-Dimer

Rapid test for the determination of specific antibodies and p24 antigen of the human immunodeficiency virus.

HIV 1/2 and p24

Rapid test for the determination of specific antibodies to hepatitis B and C.

Hepatitis B / C

Partners

We are grateful to our partners for their support in the development and production of rapid tests.

Partnership

Wholesale orders and distribution

If you are interested in a wholesale order or distribution of our products, please leave your contact information, we will definitely contact you!
Clicking on the button, you agree to the privacy policy